Last reviewed · How we verify
Zonisamide Oral Product
At a glance
| Generic name | Zonisamide Oral Product |
|---|---|
| Also known as | ZONISADE, Zonisamide oral suspension |
| Sponsor | Azurity Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures (PHASE4)
- Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study (NA)
- Characterization of Epilepsy Patients BEEP 2b (PHASE1)
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (PHASE3)
- Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT (PHASE2)
- Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy
- Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zonisamide Oral Product CI brief — competitive landscape report
- Zonisamide Oral Product updates RSS · CI watch RSS
- Azurity Pharmaceuticals portfolio CI